Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter ended June 30, 2015 (Q1 FY16)
Filing Date: July 31, 2015
This filing discloses the results of operations and financial condition for the quarter ended June 30, 2015. The company announced these results on July 30, 2015, via a press release prepared under International Financial Reporting Standards (IFRS). The filing references attached exhibits containing both Indian GAAP Unaudited Standalone Financial Results and IFRS Unaudited Consolidated Financial Results.
Key Financial Metrics
The provided text serves as a cover document referencing attached exhibits (99.1, 99.2, and 99.3) for detailed financial data. The filing text itself does not contain specific numerical values for the following metrics:
- Revenue
- Profit (Net Income)
- Cash Flow
- Margins
- Debt
- Liquidity
Note: Specific financial figures are not present in the provided text; they are contained within the referenced exhibits.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) and financial statements (Exhibits 99.2 and 99.3) for year-over-year comparisons and variance analysis.
Guidance, Outlook, and Risks
The text does not include specific management commentary, forward-looking guidance, risk factors, or contingencies. It confirms the availability of the Q1 FY16 results on the company website (www.drreddys.com) and the inclusion of review reports for the financial results.
Investor Verification Checklist
- Verify the specific revenue and profit figures in the attached IFRS Unaudited Consolidated Financial Results (Exhibit 99.3).
- Review the Indian GAAP Unaudited Standalone Financial Results (Exhibit 99.2) for local regulatory context.
- Examine the press release (Exhibit 99.1) for management commentary on the Q1 FY16 performance.
- Confirm the details of the review reports attached to the financial results.